This information was published on 2026-05-19T00:10:57 for IP Right Acceptance Published.
| Field | Value |
| (210) | 2635019 (IR 1906873) |
| (220) |
26 Jan 2026
|
| (300) |
US, 18 Dec 2025, 99555535
|
| (511) (510) |
Class 40
Providing technical information in the field of pharmaceutical manufacturing; manufacturing services for others in the field of sirna synthesis; custom manufacture of sirna therapeutics; custom manufacture of rna utilizing proprietary enzymatic technologies to enable nucleic acid therapeutics development. Class 42 Scientific research and development; research and development of small molecule RNA drugs; research and development of siRNA drugs; RNA interference technology research. |
| (540) | SIRELIS |
| (550) | Word |
| (730) |
Alnylam Pharmaceuticals, Inc.
|
Find out more about publications on the About page.